Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine “PoliovacSin”: Clinical Trials Phase I and II

Global polio eradication requires both safe and effective vaccines, and safe production processes. Sabin oral poliomyelitis vaccine (OPV) strains can evolve to virulent viruses and result in poliomyelitis outbreaks, and conventional inactivated poliomyelitis vaccine (Salk-IPV) production includes ac...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2021-05, Vol.9 (6), p.565
Main Authors: Piniaeva, Anastasia, Ignatyev, Georgy, Kozlovskaya, Liubov, Ivin, Yury, Kovpak, Anastasia, Ivanov, Alexander, Shishova, Anna, Antonova, Liliia, Khapchaev, Yusuf, Feldblium, Irina, Ivanova, Olga, Siniugina, Aleksandra, Ishmukhametov, Aydar
Format: Article
Language:English
Subjects:
Amino acids
Antibodies
Antigens
clinical trial
Clinical trials
Deactivation
Immunogenicity
inactivated vaccine
IPV
Laboratories
Neurovirulence
Placebos
Poliomyelitis
poliovirus
Sabin strain
Safety
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Global polio eradication requires both safe and effective vaccines, and safe production processes. Sabin oral poliomyelitis vaccine (OPV) strains can evolve to virulent viruses and result in poliomyelitis outbreaks, and conventional inactivated poliomyelitis vaccine (Salk-IPV) production includes accumulation of large stocks of neurovirulent wild polioviruses. Therefore, IPV based on attenuated OPV strains seems a viable option. To increase the global supply of affordable inactivated vaccine in the still not-polio free world we developed an IPV made from the Sabin strains–PoliovacSin. Clinical trials included participants 18–60 years of age. A phase I single-center, randomized, double-blind placebo-controlled clinical trial included 60 participants, who received one dose of PoliovacSin or Placebo. A phase II multicenter, randomized, double-blind, comparative clinical trial included 200 participants, who received one dose of PoliovacSin or Imovax Polio. All vaccinations were well tolerated, and PoliovacSin had a comparable safety profile to the Placebo or the reference Imovax Polio preparations. A significant increase in neutralizing antibody levels to polioviruses types 1–3 (Sabin and wild) was observed in PoliovacSin and Imovax Polio vaccinated groups. Therefore, clinical trials confirmed good tolerability, low reactogenicity, and high safety profile of the PoliovacSin and its pronounced immunogenic properties. The preparation was approved for clinical trials involving infants.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9060565